This record was last updated July 13, 2023 (before its estimated December 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
In this study, participants with high risk non-muscle-invasive bladder cancer (NMIBC) who are BCG Naïve or BCG Unresponsive and are considered ineligible for or have refused to undergo radical cystectomy, will receive RC48-ADC in combination with gemcitabine.